Moomoo AI 已提取核心訊息
Intelligent Bio Solutions Inc. has successfully regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement, as per a letter received from Nasdaq on January 2, 2024. The company had previously been notified of non-compliance due to its stockholders' equity falling short of the required $2.5 million, as reported in its September 30, 2023, quarterly report. To address this, Intelligent Bio Solutions submitted a compliance plan on December 15, 2023, which included a pro forma balance sheet showing a stockholders' equity of $4,240,629 as of October 31, 2023. This increase was primarily due to a public offering of the company's securities that closed on October 4, 2023. While Nasdaq has acknowledged the company's current compliance, it has also indicated that failure to demonstrate continued compliance in the upcoming quarterly report for the period ending December 31, 2023, could result in delisting. Additionally, as of November 15, 2023, the company did not meet the alternative compliance standards related to market value of listed securities or net income from continuing operations.
Intelligent Bio Solutions Inc. has successfully regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement, as per a letter received from Nasdaq on January 2, 2024. The company had previously been notified of non-compliance due to its stockholders' equity falling short of the required $2.5 million, as reported in its September 30, 2023, quarterly report. To address this, Intelligent Bio Solutions submitted a compliance plan on December 15, 2023, which included a pro forma balance sheet showing a stockholders' equity of $4,240,629 as of October 31, 2023. This increase was primarily due to a public offering of the company's securities that closed on October 4, 2023. While Nasdaq has acknowledged the company's current compliance, it has also indicated that failure to demonstrate continued compliance in the upcoming quarterly report for the period ending December 31, 2023, could result in delisting. Additionally, as of November 15, 2023, the company did not meet the alternative compliance standards related to market value of listed securities or net income from continuing operations.
根據納斯達克於2024年1月2日收到的一封信，Intelligent Bio Solutions Inc.已成功恢復遵守納斯達克資本市場的最低股東權益要求。該公司此前曾收到違規通知，原因是其股東權益低於2023年9月30日季度報告中公佈的所需的250萬美元。爲了解決這個問題，Intelligent Bio Solutions於2023年12月15日提交了一份合規計劃，其中包括一份預計資產負債表，該資產負債表顯示截至2023年10月31日的股東權益爲4,240,629美元。這一增長主要是由於公司證券的公開發行於2023年10月4日結束。儘管納斯達克已經承認了該公司目前的合規情況，但它也表示，未能在即將發佈的截至2023年12月31日的季度報告中證明持續合規，可能會導致退市。此外，截至2023年11月15日，該公司未達到與上市證券市值或持續經營淨收益相關的替代合規標準。
根據納斯達克於2024年1月2日收到的一封信，Intelligent Bio Solutions Inc.已成功恢復遵守納斯達克資本市場的最低股東權益要求。該公司此前曾收到違規通知，原因是其股東權益低於2023年9月30日季度報告中公佈的所需的250萬美元。爲了解決這個問題，Intelligent Bio Solutions於2023年12月15日提交了一份合規計劃，其中包括一份預計資產負債表，該資產負債表顯示截至2023年10月31日的股東權益爲4,240,629美元。這一增長主要是由於公司證券的公開發行於2023年10月4日結束。儘管納斯達克已經承認了該公司目前的合規情況，但它也表示，未能在即將發佈的截至2023年12月31日的季度報告中證明持續合規，可能會導致退市。此外，截至2023年11月15日，該公司未達到與上市證券市值或持續經營淨收益相關的替代合規標準。
有用
沒用